Public record intelligence for the path to market
A source-led view of what biotech, medical-device and healthcare-services companies disclose before they become public
02 · Sector tracks
Biotech + pharma
Track pipeline stage, trial evidence, regulatory correspondence, licenses, milestone obligations and runway to the next value event
Device + diagnostics
Separate 510(k), De Novo and PMA pathways; connect clinical evidence to quality systems, manufacturing dependencies and reimbursement
Healthcare services
Focus on payer mix, reimbursement exposure, provider and facility footprint, cohort economics, acquisitions and compliance controls
03 · Readiness builder
Choose the operating model and current stage. The output reorganizes the workstreams that usually need owners, source files and a review trail
04 · Biotech evidence matrix
A biotech evidence system should keep the same workstreams from discovery through public-company preparation. What changes is the depth, the reader and the standard of proof
Does the current narrative match the underlying program, timeline and transaction objective?
Are runway, capitalization, funding history and use of proceeds internally consistent?
Is ownership clean across patents, licenses, inventions, material contracts and obligations?
Can every scientific or clinical claim be traced to a current protocol, report or dataset?
Do submissions, agency correspondence and development strategy tell one continuous story?
Can the process, batch history, quality system and supply obligations support the next stage?
Are market, access, competition and launch assumptions distinguishable from evidence?
Are board oversight, key-person risk, incentives and decision rights ready for scrutiny?
Does each material S-1 statement have an owner, support file, reviewer and change history?
Reading boundary This matrix evaluates evidence readiness, not software. The separate data-room selection guide compares documented provider use cases and discloses this site's commercial interest
05 · Field guides
The matrix above describes the structure. These guides work through it from the point of view of the person actually asking for the evidence, because a checklist is only useful once you know who is reading it
06 · Methodology
The current guides distinguish public rules, source records and provider-stated product descriptions. Issuer records on this site link to their SEC filings, and we do not publish a market statistic without a reproducible source trail
S-1 and S-1/A disclosures, EFFECT notices, 424B4 prospectuses, filing exhibits and structured financial facts
EDGAR APIs ↗Study status, phase, sponsor, enrollment, endpoints and result availability for registered clinical studies
ClinicalTrials.gov API ↗Drug approvals and device records including 510(k), De Novo, PMA and post-approval study information
FDA databases ↗No issuer ranking, readiness score or market statistic is published until the underlying definition and sample can be reproduced